GLP-1 formulations and their uses

WO2025240560A3PCT designated stage Publication Date: 2026-01-08ROSE PHARMA INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/029273
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-05-15
Filing Date
2025-05-14
Publication Date
2026-01-08

Smart Images

  • Figure US2025029273_08012026_PF_FP_ABST
    Figure US2025029273_08012026_PF_FP_ABST
Patent Text Reader

Abstract

The GLP-1 agonist ROSE-010 may be administered in a manner that results in less side effects, and / or be more effective to achieve certain desired results than some other GLP-1 agonists, for example longer acting GLP-1 agonists.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Val (8) GLP-1 Composition and Method for Treating Functional Dyspepsia and / or Irritable Bowel Syndrome

    US20140187490A1

  • Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

    US20210169987A1